Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 147,300 shares, a decline of 38.3% from the April 15th total of 238,700 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average trading volume of […]
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its price objective hoisted by Cantor Fitzgerald from $2.00 to $4.00 in a research note released on Tuesday, The Fly reports. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2023 earnings at ($0.41) EPS. CRVS has been the topic of several other reports. Mizuho reiterated a neutral rating […]
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its target price raised by Cantor Fitzgerald from $2.00 to $4.00 in a research report sent to investors on Tuesday morning, The Fly reports. Other research analysts also recently issued research reports about the stock. StockNews.com initiated coverage on shares of Corvus Pharmaceuticals in a research report on […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) – Equities researchers at Cantor Fitzgerald upped their FY2023 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research report issued on Tuesday, May 9th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.41) per share for the year, up from […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the stock. Separately, Mizuho restated a neutral rating and issued a $3.50 price target on shares of Corvus Pharmaceuticals in a report on Thursday, March 30th. Corvus […]